Myasthenia Gravis Pipeline Analysis report covers 17 drugs currently in different phases of development. Myasthenia gravis (MG) is a neuromuscular disorder caused by impaired communication between nerves and muscles leading to the weakness and fatigue of the skeletal muscles. Symptoms of MG include slurred anf troubled speech, problems walking and lifting of objects, facial paralysis, difficulty in breathing, swallowing and chewing, extreme fatigue and double vision. It happens when normal communication between the nerve and muscle is interrupted at the neuromuscular junction—the place where nerve cells connect with the muscles they control.
The report provides Myasthenia Gravis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Akari Therapeutics, Bristol-Myers Squibb, Curavac, GT Biopharma, Inc. and Ra Pharmaceuticals among others.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration